Professor Lorenz Hofbauer, CRTD member and Director of the Center for Healthy Aging at Universitätsklinikum Carl Gustav Carus, has completed a large clinical phase 3-study with colleagues from eight countries on over 7.000 women with osteoporosis. In the FRAME study, the monoclonal antibody against sclerostin named romosozumab was evaluated over one year in women with osteoporosis after menopause. Treatment with romosozumab reduced the risk of fractures by up to 73%. The study was published in the New England Journal of Medicine publiziert (DOI: 10.1056/NEJMoa1607948).
Further information at amgen.com